Report cover image

Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034

Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319800

Description

The chronic obstructive pulmonary disease (COPD) market size was valued at USD 18.40 Billion in 2024, driven by the increased tobacco consumption across the 7 major markets. The market is expected to grow at a CAGR of 5.30% during the forecast period of 2025-2034, with the values likely to reach USD 30.84 Billion by 2034.

Chronic Obstructive Pulmonary Disease (COPD): Introduction

Chronic obstructive pulmonary disease (COPD) is a common lung disease in which a patient suffers from breathing issues because the airflow gets restricted. It is also known as emphysema or chronic bronchitis. There are chances that lungs may get clogged with phlegm in people suffering from it. The symptoms of chronic obstructive pulmonary disease include cough (with or without phlegm), breathing issues, wheezing, and exhaustion. The most common causes of chronic obstructive pulmonary disease include smoking and air pollution.

Chronic Obstructive Pulmonary Disease (COPD) Market Analysis

The increasing prevalence of chronic obstructive pulmonary disease within the 7 major markets is directly contributing to the chronic obstructive pulmonary disease market demand. The increase in COPD prevalence is due to several factors such as increasing aging population, increased urbanization, and other lifestyle habits. As people age, they are more susceptible to developing COPD due to decreased immunity rates with age. The increasing population of vehicles has been contributing to a rise in pollution levels in the urban cities and with the population density being high, it is directly contributing to the rise in COPD. Additionally, increased involvement of smoking and decreased health maintenance contributes to the rise in number of cases.

The chronic obstructive pulmonary disease market growth is driven by the advent of novel treatment alternatives for patients. In March 2023, Sanofi revealed that their potential COPD drug called Dupixent® showed favourable results in the Phase 3 trials. It is the first and only biologic to demonstrate a 30% reduction in acute as well as moderate exacerbations of COPD.

In addition to pharmacological treatments, surgical interventions like the lung volume reduction surgery, bullectomy and lung transplant are also being used on patients with severe conditions. With the prevalence of personalised treatments and targeted biologics, triple drug combinations that include the use of long-acting beta antagonists (LABAs), long-acting muscarinic antagonists (LAMA), and inhaled steroids are being considered as a valid treatment alternative. As research continues to progress, we can anticipate some significant treatment breakthroughs in the coming years, which will contribute significantly to the chronic obstructive pulmonary disease market share in the future.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation

“Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type
  • Drugs
  
  • Bronchodilator Monotherapy Short-Acting Beta-2 Agonists Long-Acting Beta-2 Agonists Others

  •   
  • Anti-Inflammatory Drugs Oral and Inhaled Corticosteroids Anti-Leukotrienes

  •   
  • Others
    • Surgery
      
  • Lung Volume Reduction Surgery

  •   
  • Lung Transplant

  •   
  • Bullectomy

  •   
  • Others
    • Oxygen Therapy
    • Others
    Market Breakup by Disease Type
    • Emphysema
    • Chronic Bronchitis
    Market Breakup by Route of Administration
    • Oral
    • Inhalation
    • Parenteral
    Market Breakup by Region
    • United States
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Japan
    Chronic Obstructive Pulmonary Disease (COPD) Market Overview

    The United States held a substantial portion of the chronic obstructive pulmonary disease market share during the historical period. Factors like a prominent healthcare ecosystem, coupled with core MedTech companies prevailing in the area contributed to the significant market growth. This trend is expected to continue, with the launch of several informative initiatives like the Learn More Breathe Better® Community Subcontract Program, which is organised by the National Heart, Lung, and Blood Institute (NHLBI). This program offers funding to organisations all over the country to offer better health education initiatives.

    As a hub of medical inventions, Europe has been a key player in the COPD market. Having significant research and academic institutions along with a well-equipped infrastructure fosters major scope for the development of groundbreaking treatments.

    The Asia Pacific region is home to various developing countries undergoing rapid urbanisation. As a result, the population living in the region is more susceptible to developing COPD due to higher exposure to pollution levels. Moreover, countries like Japan and China have a massive size of geriatric population, leaving the countries at an increased risk of facing more COPD cases. Identifying the current trend, the region is experiencing essential infrastructure developments in hospitals and research labs to combat the high chronic obstructive pulmonary disease market demand that may arise in the future.

    Chronic Obstructive Pulmonary Disease (COPD) Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • GlaxoSmithKline plc (GSK)
    • AstraZeneca
    • Boehringer Ingelheim
    • Novartis
    • Teva Pharmaceutical Industries
    • Viatris (formerly Mylan)
    • Sunovion Pharmaceuticals
    • Cipla
    • Merck & Co., Inc.
    • Vectura Group
    • Pfizer Inc.
    • Regeneron Pharmaceuticals
    • Circassia Pharmaceuticals
    • Theravance Biopharma
    • Almirall
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Chronic Obstructive Pulmonary Disease (COPD) Overview
    3.1 Guidelines and Stages
    3.2 Pathophysiology
    3.3 Screening and Diagnosis
    3.4 Treatment Pathway
    4 Patient Profile
    4.1 Patient Profile Overview
    4.2 Patient Psychology and Emotional Impact Factors
    4.3 Risk Assessment and Treatment Success Rate
    5 Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Analysis – 7MM
    5.1 7MM Epidemiology Scenario Overview (2018-2034)
    5.2 United States Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3.1 Germany Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3.2 France Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3.3 Italy Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3.4 Spain Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.3.5 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    5.4 Japan Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
    6 Chronic Obstructive Pulmonary Disease (COPD) Market Overview – 7MM
    6.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
    6.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
    7 Chronic Obstructive Pulmonary Disease (COPD) Market Landscape – 7MM
    7.1 Chronic Obstructive Pulmonary Disease (COPD)Sclerosis: Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Chronic Obstructive Pulmonary Disease (COPD)Product Landscape
    7.2.1 Analysis by Disease Type
    7.2.2 Analysis by Treatment Type
    7.2.3 Analysis by Route of Administration
    8 Chronic Obstructive Pulmonary Disease (COPD)Challenges and Unmet Needs
    8.1 Treatment Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Treatment
    10 Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.3 Porter’s Five Forces Model
    10.4 Key Demand Indicators
    10.5 Key Price Indicators
    10.6 Industry Events, Initiatives, and Trends
    10.7 Value Chain Analysis
    11 Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation – 7MM
    11.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    11.1.1 Market Overview
    11.1.2 Drugs
    11.1.2.1 Bronchodilator Monotherapy
    11.1.2.1.1 Short-Acting Beta-2 Agonists
    11.1.2.1.2 Long-Acting Beta-2 Agonists
    11.1.2.1.3 Others
    11.1.2.2 Anti-Inflammatory Drugs
    11.1.2.2.1 Oral and Inhaled Corticosteroids
    11.1.2.2.2 Anti-Leukotrienes
    11.1.2.2.3 Others
    11.1.3 Surgery
    11.1.3.1 Lung Volume Reduction Surgery
    11.1.3.2 Lung Transplant
    11.1.3.3 Bullectomy
    11.1.3.4 Others
    11.1.4 Oxygen Therapy
    11.1.5 Others
    11.1.6 Chronic Obstructive Pulmonary Disease (COPD) Market by Disease Type
    11.1.6.1 Market Overview
    11.1.6.2 Emphysema
    11.1.6.3 Chronic Bronchitis
    11.1.7 Chronic Obstructive Pulmonary Disease (COPD) Market by Route of Administration
    11.1.7.1 Market Overview
    11.1.7.2 Oral
    11.1.7.3 Inhalation
    11.1.7.4 Parenteral
    11.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Region
    11.2.1 Market Overview
    11.2.2 United States
    11.2.3 EU-4 and the United Kingdom
    11.2.3.1 Germany
    11.2.3.2 France
    11.2.3.3 Italy
    11.2.3.4 Spain
    11.2.3.5 United Kingdom
    11.2.4 Japan
    12 United States Chronic Obstructive Pulmonary Disease (COPD)Market
    12.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
    12.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
    12.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    12.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    13 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD)Market
    13.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
    13.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
    13.3 Germany Chronic Obstructive Pulmonary Disease (COPD) Market Overview
    13.3.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    13.3.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    13.4 France Chronic Obstructive Pulmonary Disease (COPD) Market Overview
    13.4.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    13.4.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    13.5 Italy Chronic Obstructive Pulmonary Disease (COPD) Market Overview
    13.5.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    13.5.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    13.6 Spain Chronic Obstructive Pulmonary Disease (COPD) Market Overview
    13.6.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    13.6.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    13.7 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Market Overview
    13.7.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    13.7.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    14 Japan Chronic Obstructive Pulmonary Disease (COPD)Market
    14.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
    14.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
    14.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
    14.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
    15 Regulatory Framework
    15.1 Regulatory Overview
    15.1.1 US FDA
    15.1.2 EU EMA
    15.1.3 JAPAN PMDA
    16 Patent Analysis
    16.1 Analysis by Type of Patent
    16.2 Analysis by Publication year
    16.3 Analysis by Issuing Authority
    16.4 Analysis by Patent Age
    16.5 Analysis by CPC Analysis
    16.6 Analysis by Patent Valuation
    16.7 Analysis by Key Players
    17 Grants Analysis
    17.1 Analysis by year
    17.2 Analysis by Amount Awarded
    17.3 Analysis by Issuing Authority
    17.4 Analysis by Grant Application
    17.5 Analysis by Funding Institute
    17.6 Analysis by NIH Departments
    17.7 Analysis by Recipient Organization
    18 Clinical Trials Analysis
    18.1 Analysis by Trial Registration Year
    18.2 Analysis by Trial Status
    18.3 Analysis by Trial Phase
    18.4 Analysis by Therapeutic Area
    18.5 Analysis by Geography
    19 Funding and Investment Analysis
    19.1 Analysis by Funding Instances
    19.2 Analysis by Type of Funding
    19.3 Analysis by Funding Amount
    19.4 Analysis by Leading Players
    19.5 Analysis by Leading Investors
    19.6 Analysis by Geography
    20 Partnerships and Collaborations Analysis
    20.1 Analysis by Partnership Instances
    20.2 Analysis by Type of Partnership
    20.3 Analysis by Leading Players
    20.4 Analysis by Geography
    21 Supplier Landscape
    21.1 GlaxoSmithKline plc (GSK)
    21.1.1 Financial Analysis
    21.1.2 Product Portfolio
    21.1.3 Demographic Reach and Achievements
    21.1.4 Mergers and Acquisitions
    21.1.5 Certifications
    21.2 AstraZeneca
    21.2.1 Financial Analysis
    21.2.2 Product Portfolio
    21.2.3 Demographic Reach and Achievements
    21.2.4 Mergers and Acquisitions
    21.2.5 Certifications
    21.3 Boehringer Ingelheim
    21.3.1 Financial Analysis
    21.3.2 Product Portfolio
    21.3.3 Demographic Reach and Achievements
    21.3.4 Mergers and Acquisitions
    21.3.5 Certifications
    21.4 Novartis
    21.4.1 Financial Analysis
    21.4.2 Product Portfolio
    21.4.3 Demographic Reach and Achievements
    21.4.4 Mergers and Acquisitions
    21.4.5 Certifications
    21.5 Teva Pharmaceutical Industries
    21.5.1 Financial Analysis
    21.5.2 Product Portfolio
    21.5.3 Demographic Reach and Achievements
    21.5.4 Mergers and Acquisitions
    21.5.5 Certifications
    21.6 Viatris (formerly Mylan)
    21.6.1 Financial Analysis
    21.6.2 Product Portfolio
    21.6.3 Demographic Reach and Achievements
    21.6.4 Mergers and Acquisitions
    21.6.5 Certifications
    21.7 Sunovion Pharmaceuticals
    21.7.1 Financial Analysis
    21.7.2 Product Portfolio
    21.7.3 Demographic Reach and Achievements
    21.7.4 Mergers and Acquisitions
    21.7.5 Certifications
    21.8 Cipla
    21.8.1 Financial Analysis
    21.8.2 Product Portfolio
    21.8.3 Demographic Reach and Achievements
    21.8.4 Mergers and Acquisitions
    21.8.5 Certifications
    21.9 Merck & Co., Inc.
    21.9.1 Financial Analysis
    21.9.2 Product Portfolio
    21.9.3 Demographic Reach and Achievements
    21.9.4 Mergers and Acquisitions
    21.9.5 Certifications
    21.10 Vectura Group
    21.10.1 Financial Analysis
    21.10.2 Product Portfolio
    21.10.3 Demographic Reach and Achievements
    21.10.4 Mergers and Acquisitions
    21.10.5 Certifications
    21.11 Pfizer Inc.
    21.11.1 Financial Analysis
    21.11.2 Product Portfolio
    21.11.3 Demographic Reach and Achievements
    21.11.4 Mergers and Acquisitions
    21.11.5 Certifications
    21.12 Regeneron Pharmaceuticals
    21.12.1 Financial Analysis
    21.12.2 Product Portfolio
    21.12.3 Demographic Reach and Achievements
    21.12.4 Mergers and Acquisitions
    21.12.5 Certifications
    21.13 Circassia Pharmaceuticals
    21.13.1 Financial Analysis
    21.13.2 Product Portfolio
    21.13.3 Demographic Reach and Achievements
    21.13.4 Mergers and Acquisitions
    21.13.5 Certifications
    21.14 Theravance Biopharma
    21.14.1 Financial Analysis
    21.14.2 Product Portfolio
    21.14.3 Demographic Reach and Achievements
    21.14.4 Mergers and Acquisitions
    21.14.5 Certifications
    21.15 Almirall
    21.15.1 Financial Analysis
    21.15.2 Product Portfolio
    21.15.3 Demographic Reach and Achievements
    21.15.4 Mergers and Acquisitions
    21.15.5 Certifications
    22 Chronic Obstructive Pulmonary Disease (COPD)Market- Distribution Model (Additional Insight)
    22.1 Overview
    22.2 Potential Distributors
    22.3 Key Parameters for Distribution Partner Assessment
    23 Key Opinion Leaders (KOL) Insights (Additional Insight)
    24 Company Competitiveness Analysis (Additional Insight)
    24.1 Very Small Companies
    24.2 Small Companies
    24.3 Mid-Sized Companies
    24.4 Large Companies
    24.5 Very Large Companies
    25 Payment Methods (Additional Insight)
    25.1 Government Funded
    25.2 Private Insurance
    25.3 Out-of-Pocket
    How Do Licenses Work?
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.